David Hansen serves as the President, Chief Executive Officer, and Chairman of the Board of Directors. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience. He has held senior management roles in both private startup companies as well as small to mid-sized public companies. His senior level experience includes executive management, finance and accounting, corporate development, and sales and marketing. During his career, he has executed a wide variety of in and out licensing agreements, research and development collaborations, joint ventures, divestitures, and acquisitions. He has developed expertise in the therapeutic areas of immunology, oncology, and infectious disease. He gained executive management experience at several life sciences companies prior to co-founding the Company, making him particularly suited for his leadership role at MabVax. He was a corporate officer of Avanir Pharmaceuticals where he held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences in which is was a founder. Prior to Avanir, he served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development. He has additional management experience with Merck & Co. (Schering-Plough), Key Pharmaceuticals, and Bristol Myers Squibb.

Gregory P. Hanson, C.M.A., M.B.A., serves as the CFO of MabVax. Mr. Hanson has over 30 years' experience serving as the CFO, financial executive and board member of public and private life sciences and hi-tech companies. Since October 2016, he has served as a member of the board of directors of WCCT, Inc., a private pharmaceutical contract research organization. Previously, Mr. Hanson served on the Advisory Board of Menon International and Brinson Patrick Securities. His executive level experience includes CFO at Avanir Pharmaceuticals and Mast Therapeutics and investment banking at Brinson Patrick Securities. Mr. Hanson is Past-President and 11-year Member of the Board of Directors of San Diego Financial Executives International (FEI). Mr. Hanson was a founding and 6-year member of the Small Business Advisory Committee to the Financial Accounting Standards Board (FASB), and has spoken at various national conferences, industry organizations and panels on financing strategy and mergers and acquisitions, and twice spoken to the SEC's Committee on Improvements to Financial Reporting.

Mr. Hanson has passed the examination for Certified Public Accountants and is a Certified Management Accountant. He has an MBA with distinction from the University of Michigan, and a BS in Mechanical Engineering from Kansas State University. From 2008 to September 2016 Mr. Hanson maintained Series 7 & Series 63 securities licenses. 

Philip O. Livingston, M.D. serves as a member of the Board of Directors and Chief Science Officer and, prior to the Merger, served as a member of the Board of Directors and Chief Science Officer of MabVax Therapeutics, Inc. from 2012. Dr. Livingston received his M.D. degree from Harvard Medical School, was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University, and also Attending Physician and Member in Memorial Sloan-Kettering Cancer Center (MSKCC), where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years until his retirement from MSKCC on October 1, 2011. HIs research focused on identification of suitable targets for immunotherapy of a variety of cancers, construction of polyvalent conjugate vaccines specifically designed to augment antibody responses against these targets, and identification of optimal immunological adjuvants to further augment the potency of these vaccines. He has more than 150 publications and four issued and three pending patents concerning cancer vaccines. Recently, he helped establish MabVax Therapeutics, Inc., and another biotech company, Adjuvance Technologies, Inc. MabVax Inc. supports two randomized Phase II trials with these MSK polyvalent vaccines and establishment of human monoclonal antibodies from the blood of immunized patients. The Company believes that Dr. Livingston's extensive expertise in immunotherapy qualifies him to serve as a member of the Board of Directors and Chief Science Officer.